Live feed
·
PRReleasevia Quantisnow
PureTech Health plc logo

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

ByQuantisnow·Wall Street's wire, on your screen.
PRTC· PureTech Health plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRTC (PureTech Health plc) and more on Quantisnow.